Ophthalmology

Dry Eye Associated With Living Near Industrial Zones, Exposure to Sulfur Dioxide

June 12th 2024

Expanding ways to treat eye pain could reduce the burden on the emergency department (ED) and other areas of the health care system.

Woman rubbing eyes | Image credit: Yakobchuk Olena - stock.adobe.com

Double-Dose Aflibercept Relieved Treatment Burden, Displayed Anatomic Gains Compared With Regular Dose

June 5th 2024

Blue eye | Image credit: Vladimir Voronin - stock.adobe.com

First Aflibercept Biosimilars Approved in US

May 23rd 2024

Close of up of an older woman's eye | Image credit: Syda Productions - stock.adobe.com

By Skylar Jeremias

May 20th 2024

Woman's Eyes | Image credit: Africa Studio - stock.adobe.com

Visual Acuity, Retinal Sensitivity Improved With Intravitreal Ranibizumab Injection

May 14th 2024

Continuing Medical Education

1.0 Credit / Ophthalmology/Optometry

Maximizing Patient Outcomes in Ophthalmologic Diseases: How Managed Care Professionals Play a Key Role in Facilitating Uptake of Biosimilars

2.0 Credits / Ophthalmology

Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care

1.5 Credits / Ophthalmology, Optometry

Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies

1.5 Credits / Ophthalmology, Optometry

Patient-Centered Treatment Plans for Management of Neovascular (Wet) AMD and Diabetic Macular Edema: Insights on Recent Efficacy, Safety, and Real-World Data to Improve Adherence and Outcomes

Continuing Medical Education

View All

On-Demand Webinar

Maximizing Patient Outcomes in Ophthalmologic Diseases: How Managed Care Professionals Play a Key Role in Facilitating Uptake of Biosimilars

1.0 Credit / Ophthalmology/Optometry

AJMC Supplement

Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care

2.0 Credits / Ophthalmology

On-Demand Virtual Symposium

Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies

1.5 Credits / Ophthalmology, Optometry

More News

May 23rd 2023

Failure to Attend Follow-up Is the Main Reason for Discontinuation of Amblyopia Therapy

About 69% of pediatric patients had discontinued amblyopia therapy during COVID-19 even as their parents reported that adherence was good.

May 16th 2023

Bevacizumab First-line Treatment More Cost-effective in RVO vs Aflibercept

Aflibercept was a less cost-effective treatment for retinal vein occlusion (RVO) compared with bevacizumab, although visual acuity outcomes were similar.

May 9th 2023

Myopia Associated With Increased Risk of POAG

The relationship between myopia and primary open-angle glaucoma (POAG) was stronger in Asian, Black, and Hispanic individuals compared with White individuals.

May 3rd 2023

AI Cannot Assist in Prepping for Ophthalmology Board Certification Exams, Study Finds

When presented with a set of multiple choice questions used to help trainees practice for the ophthalmology board certification exams, the artificial intelligence (AI) chatbot ChatGPT was able to answer only half correctly.

April 26th 2023

Average Acuity-Based Outcomes Improved With Eyeglasses Using 0.05D Steps

Researchers found that eyeglasses with traditional steps of 0.25D were less effective and less preferred by participants compared with those refracted in 0.05D steps.

April 17th 2023

ROP Incidence Increased in Premature Infants

Retinopathy of prematurity (ROP) was found to have increased from 2003 to 2019, especially in Black and Hispanic children.

April 17th 2023

Dr Darius Moshfeghi Outlines the Impact of Delayed Treatment in ROP

Retinopathy of prematurity (ROP) that occurs in preterm babies can progress fast, which requires quick decisions early about treatment, explained Darius M. Moshfeghi, MD, chief, Retina Division, and professor at the Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine.

April 12th 2023

Perfluorohexyloctane Reduced Signs and Symptoms of Dry Eye Disease

Perfluorohexyloctane (NOV03) was able to reduce the signs and symptoms of dry eye disease (DED) when compared with hypotonic saline control and was well tolerated.

April 10th 2023

Dr Charles Wykoff: Some Patients May Need Both Gene Therapy and Anti-VEGF to Treat Wet AMD

While there are benefits of gene therapy, some patients will continue to need anti–vascular endothelial growth factor (VEGF) therapy to treat wet age-related macular degeneration (AMD), said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.

April 3rd 2023

First-year Single Eye Treatment Cost Lowest With Bevacizumab for AMD, DME

Treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME) for a single year was found to be lowest when using bevacizumab.

April 3rd 2023

Switching From Aflibercept to Bevacizumab Results in Cost Savings Without Sacrificing Visual Acuity, Says Dr Jennifer Sun

The Protocol AC study analyzed visual acuity gains and cost if patients with diabetic macular edema started on bevacizumab, which costs less, and switched to aflibercept later, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.

March 30th 2023

Trajectory of Treatment Landscape for Wet AMD and DME

In their closing thoughts, the expert panelists discuss the future of the disease state and treatment options, and how they expect provider, patient, and payer value perception to change in the future.

March 30th 2023

Payer Engagement With the Retina Community

The panelists discuss how payers can best engage with the retinal disease community on a provider and patient level.

Screenshot of Eleonora Lad, MD, PhD, smiling

March 26th 2023

Dr Eleonora Lad: Early Intervention for Geographic Atrophy Prevents Too Much Irreversible Damage

The first FDA-approved therapy for geographic atrophy, pegcetacoplan, slows disease progression but does not reverse it, which means providers need to intervene early before there is too much irreversible damage, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.

March 23rd 2023

Evolution of Access to Treatment for Wet AMD/DME Therapies

Dr Sheth discusses the evolution of access to treatment for AMD/DME over the past few years and initiatives to expand treatment access.

March 23rd 2023

Wet AMD Resource Utilization Impacted by Medication Duration of Action

Joseph Coney, MD, FASRS, FACS, discusses switching anti-VEGF agents in the treatment of wet AMD and what payers should consider when switching anti-VEGF therapies.

March 21st 2023

Estimates of Diabetic Retinopathy Incidence, Progression Lower Than Previously Reported in American Indians

American Indians and Alaska Native individuals had lower estimates of incidence of diabetic retinopathy than had been reported.

March 16th 2023

Utilization Management Strategies in Treatment of Wet AMD and DME

Veeral Sheth, MD, MBA, FACS, Joseph Coney, MD, FASRS, FACS, and Caesar Luo, MD, FASRS, FACS discuss their experience with utilization management strategies.

March 16th 2023

Treatment Barriers Facing Patients With DME and Wet AMD

Caesar Luo, MD, FASRS, FACS discusses the biggest barriers for patients with wet AMD and DME to receiving optimal treatment and his strategies to overcome these barriers.

March 15th 2023

Treatments for DED Associated With MGD Require Future Evaluation, Development

A systematic review found that there were currently a limited number of clinical trials evaluating treatment for dry eye disease (DED) that is associated with meibomian gland dysfunction (MGD).

March 9th 2023

Faster Rates of GCIPL, cpRNFL Thinning Associated With Higher Risks of Glaucoma

Ganglion cell/inner plexiform layer (GCIPL) and circumpapillary retinal nerve fiber layer (cpRNFL) thinning were both associated with a higher risk of developing perimetric glaucoma.

March 9th 2023

Diagnostic Imaging Impacting DME and Wet AMD Treatment Landscape

A panel of medical experts discuss diagnostic imaging surrounding DME and wet AMD.

March 9th 2023

Novel Treatment Mechanisms for Patients with DME and Wet AMD

Drs Coney, Luo, and Sheth discuss potential novel treatment mechanisms or options that we could see in the future with wet AMD and DME.

Screenshot of Eleonora Lad, MD, PhD, smiling during a Zoom video interview

March 5th 2023

Pegcetacoplan Approval a “Dream Come True” for Patients With Geographic Atrophy, Says Dr Eleonora Lad

Pegcetacoplan was approved by the FDA to treat geographic atrophy (GA), providing a treatment option for patients who previously had none, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.

March 2nd 2023

Clinical Considerations for Retreatment in Failed Anti-VEGF Therapy

Veeral Sheth, MD, MBA, FACS discusses re-treatment in patients with wet AMD who have previously failed an anti-VEGF therapy.

March 2nd 2023

Faricimab Approved Label Dosing Interval

Dr Coney expands on the role and impact of approved label dosing of faricimab.

March 2nd 2023

Amsler Grid Test Not Recommended for Early AMD Detection

A recent review found that the performance of the Amsler grid test was not at a level that was recommended for detecting early or dry age-related macular degeneration (AMD).

March 1st 2023

Cataract Surgery in Children Commonly Led to Glaucoma-Related Adverse Events